-DOCSTART- -X- O
Chikungunya -X- _ O
virus -X- _ O
( -X- _ O
CHIKV -X- _ O
) -X- _ O
is -X- _ O
a -X- _ O
mosquito-borne -X- _ O
alphavirus -X- _ O
that -X- _ O
re-emerged -X- _ O
in -X- _ O
2004 -X- _ O
and -X- _ O
has -X- _ O
caused -X- _ O
massive -X- _ O
outbreaks -X- _ O
in -X- _ O
recent -X- _ O
years. -X- _ O
The -X- _ O
lack -X- _ O
of -X- _ O
a -X- _ O
licensed -X- _ O
vaccine -X- _ O
or -X- _ O
treatment -X- _ O
options -X- _ O
emphasize -X- _ O
the -X- _ O
need -X- _ O
to -X- _ O
obtain -X- _ O
more -X- _ O
insight -X- _ O
into -X- _ O
the -X- _ O
viral -X- _ O
life -X- _ O
cycle -X- _ O
and -X- _ O
CHIKV-host -X- _ O
interactions. -X- _ O
Infectious -X- _ O
cDNA -X- _ O
clones -X- _ O
are -X- _ O
important -X- _ O
tools -X- _ O
for -X- _ O
such -X- _ O
studies -X- _ O
, -X- _ O
and -X- _ O
for -X- _ O
mechanism -X- _ O
of -X- _ O
action -X- _ O
studies -X- _ O
on -X- _ O
antiviral -X- _ O
compounds. -X- _ O
Existing -X- _ O
CHIKV -X- _ O
cDNA -X- _ O
clones -X- _ O
are -X- _ O
based -X- _ O
on -X- _ O
a -X- _ O
single -X- _ O
genome -X- _ O
from -X- _ O
an -X- _ O
individual -X- _ O
clinical -X- _ O
isolate -X- _ O
, -X- _ O
which -X- _ O
is -X- _ O
expected -X- _ O
to -X- _ O
have -X- _ O
evolved -X- _ O
specific -X- _ O
characteristics -X- _ O
in -X- _ O
response -X- _ O
to -X- _ O
the -X- _ O
host -X- _ O
environment -X- _ O
, -X- _ O
and -X- _ O
possibly -X- _ O
also -X- _ O
during -X- _ O
subsequent -X- _ O
cell -X- _ O
culture -X- _ O
passaging. -X- _ O
To -X- _ O
obtain -X- _ O
a -X- _ O
virus -X- _ O
expected -X- _ O
to -X- _ O
have -X- _ O
the -X- _ O
general -X- _ O
characteristics -X- _ O
of -X- _ O
the -X- _ O
recent -X- _ O
E1-226V -X- _ O
CHIKV -X- _ O
isolates -X- _ O
, -X- _ O
we -X- _ O
have -X- _ O
constructed -X- _ O
a -X- _ O
new -X- _ O
CHIKV -X- _ O
full-length -X- _ O
cDNA -X- _ O
clone -X- _ O
, -X- _ O
CHIKV -X- _ B-Patient
LS3 -X- _ I-Patient
, -X- _ O
based -X- _ O
on -X- _ O
the -X- _ O
consensus -X- _ O
sequence -X- _ O
of -X- _ O
their -X- _ O
aligned -X- _ O
genomes. -X- _ O
Here -X- _ O
we -X- _ O
report -X- _ O
the -X- _ O
characterization -X- _ O
of -X- _ O
this -X- _ O
synthetic -X- _ B-Patient
virus -X- _ I-Patient
and -X- _ I-Patient
a -X- _ I-Patient
green -X- _ I-Patient
fluorescent -X- _ I-Patient
protein-expressing -X- _ I-Patient
variant -X- _ I-Patient
( -X- _ I-Patient
CHIKV -X- _ I-Patient
LS3-GFP -X- _ I-Patient
) -X- _ I-Patient
. -X- _ O
Their -X- _ O
characteristics -X- _ O
were -X- _ O
compared -X- _ O
to -X- _ O
those -X- _ O
of -X- _ O
natural -X- _ B-Comparison
strain -X- _ I-Comparison
ITA07-RA1 -X- _ I-Comparison
, -X- _ O
which -X- _ O
was -X- _ O
isolated -X- _ O
during -X- _ O
the -X- _ O
2007 -X- _ O
outbreak -X- _ O
in -X- _ O
Italy. -X- _ O
In -X- _ O
cell -X- _ O
culture -X- _ O
the -X- _ O
synthetic -X- _ B-Outcome
viruses -X- _ I-Outcome
displayed -X- _ I-Outcome
phenotypes -X- _ I-Outcome
comparable -X- _ I-Outcome
to -X- _ I-Outcome
the -X- _ I-Outcome
natural -X- _ I-Outcome
isolate -X- _ I-Outcome
, -X- _ I-Outcome
and -X- _ I-Outcome
in -X- _ I-Outcome
a -X- _ I-Outcome
mouse -X- _ I-Outcome
model -X- _ I-Outcome
they -X- _ I-Outcome
caused -X- _ I-Outcome
lethal -X- _ I-Outcome
infections -X- _ I-Outcome
that -X- _ I-Outcome
were -X- _ I-Outcome
indistinguishable -X- _ I-Outcome
from -X- _ I-Outcome
infections -X- _ I-Outcome
with -X- _ I-Outcome
a -X- _ I-Outcome
natural -X- _ I-Outcome
strain. -X- _ I-Outcome
Compared -X- _ I-Outcome
to -X- _ I-Outcome
ITA07-RA1 -X- _ I-Outcome
and -X- _ I-Outcome
clinical -X- _ I-Outcome
isolate -X- _ I-Outcome
NL10 -X- _ I-Outcome
/ -X- _ I-Outcome
152 -X- _ I-Outcome
, -X- _ I-Outcome
the -X- _ I-Outcome
synthetic -X- _ I-Outcome
viruses -X- _ I-Outcome
displayed -X- _ I-Outcome
similar -X- _ I-Outcome
sensitivities -X- _ I-Outcome
to -X- _ I-Outcome
several -X- _ I-Outcome
antiviral -X- _ I-Outcome
compounds. -X- _ I-Outcome
3-deaza-adenosine -X- _ I-Outcome
was -X- _ I-Outcome
identified -X- _ I-Outcome
as -X- _ I-Outcome
a -X- _ I-Outcome
new -X- _ I-Outcome
inhibitor -X- _ I-Outcome
of -X- _ I-Outcome
CHIKV -X- _ I-Outcome
replication. -X- _ I-Outcome
Cyclosporin -X- _ I-Outcome
A -X- _ I-Outcome
had -X- _ I-Outcome
no -X- _ I-Outcome
effect -X- _ I-Outcome
on -X- _ I-Outcome
CHIKV -X- _ I-Outcome
replication -X- _ I-Outcome
, -X- _ I-Outcome
suggesting -X- _ I-Outcome
that -X- _ I-Outcome
cyclophilins -X- _ I-Outcome
-opposite -X- _ I-Outcome
to -X- _ I-Outcome
what -X- _ I-Outcome
was -X- _ I-Outcome
found -X- _ I-Outcome
for -X- _ I-Outcome
other -X- _ I-Outcome
+RNA -X- _ I-Outcome
viruses- -X- _ I-Outcome
do -X- _ I-Outcome
not -X- _ I-Outcome
play -X- _ I-Outcome
an -X- _ I-Outcome
essential -X- _ I-Outcome
role -X- _ I-Outcome
in -X- _ I-Outcome
CHIKV -X- _ I-Outcome
replication. -X- _ I-Outcome
The -X- _ O
characterization -X- _ O
of -X- _ O
the -X- _ O
consensus -X- _ O
sequence-based -X- _ O
synthetic -X- _ O
viruses -X- _ O
and -X- _ O
their -X- _ O
comparison -X- _ O
to -X- _ O
natural -X- _ O
isolates -X- _ O
demonstrated -X- _ O
that -X- _ O
CHIKV -X- _ B-Outcome
LS3 -X- _ I-Outcome
and -X- _ I-Outcome
LS3- -X- _ I-Outcome
GFP -X- _ I-Outcome
are -X- _ I-Outcome
suitable -X- _ I-Outcome
and -X- _ I-Outcome
representative -X- _ I-Outcome
tools -X- _ I-Outcome
to -X- _ I-Outcome
study -X- _ I-Outcome
CHIKV-host -X- _ I-Outcome
interactions -X- _ I-Outcome
, -X- _ I-Outcome
screen -X- _ I-Outcome
for -X- _ I-Outcome
antiviral -X- _ I-Outcome
compounds -X- _ I-Outcome
and -X- _ I-Outcome
unravel -X- _ I-Outcome
their -X- _ I-Outcome
mode -X- _ I-Outcome
of -X- _ I-Outcome
action -X- _ I-Outcome
. -X- _ O

